Back to top

Positive Data on Array Oncology Candidate

Read MoreHide Full Article

Array BioPharma Inc. (ARRY - Free Report) recently announced positive interim results from a phase I study which is evaluating its candidate ARRY-520 combined with Onyx Pharmaceuticals, Inc.’s Kyprolis in patients suffering from relapsed or refractory multiple myeloma (MM). The results were presented at the 2013 Congress of the European Hematology Association in Sweden.

The study enrolled patients suffering from relapsed or refractory MM who were unable to tolerate Takeda Pharmaceutical Company Limited’s Velcade. Interim results from the study revealed that the combination of ARRY-520 and Kyprolis showed a disease control rate of 82% along with a clinical benefit rate of 53%. The results further revealed that the combination was well tolerated with no serious side effects.

Array also presented data on a potential patient selection marker from several studies on ARRY-520 in patients suffering from relapsed and refractory MM.

Array mentioned in its press release that data from a phase II study on ARRY-520 revealed overall survival was comparatively longer in patients with low alpha-1-acid glycoprotein (AAG) than in patients with higher AAG. This is expected to help Array to target the appropriate patient population who stand to benefit from ARRY-520 treatment.

We note that Kyprolis is indicated for the treatment of MM patients who have received at least two prior therapies including Velcade and an immunomodulatory agent. The disease had progressed in these patients on or within 60 days of completion of the last therapy.

Currently, Array BioPharma carries a Zacks Rank #3 (Hold). However, biopharma stocks such as Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) presently look better positioned with a Zacks Rank #1 (Strong Buy).

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Jazz Pharmaceuticals PLC (JAZZ) - free report >>

Array BioPharma Inc. (ARRY) - free report >>

More from Zacks Analyst Blog

You May Like